The findings of a new study suggest that the interplay between diet, microbiota and intestinal immunity regulates obesity, diabetes and other metabolic conditions.
Funds to be invested to further advance Clinical Microbiomics’ leading microbiome profiling and systems biology platform, and to expand into new offerings and markets
A gut microbial metabolite called trimethylamine N-oxide, or TMAO, could improve immunotherapy success in pancreatic cancer.
Marco Caspani, Chief Executive Officer at CSL Srl, discussed the challenges and the opportunity of producing anaerobic bacteria during the press conference on The Akkermansia Company.
Michael Oredsson, CEO at The Akkermansia Company, discussed with the new postbiotic supplement containing pastorised Akkermansia muciniphila.
Stijn Oste, Vice president Metagenics, head EMEA, presents the new supplement during the press conference held in Milan (Italy).
The findings of a new research suggest that microbiota-based therapies can help improve clinical outcomes after organ transplants.
Researchers have developed a new technique that can identify which gut microbes have migrated from the gut to the blood.
Denise Kelly (Investment Advisor at Seventure) discussed the next challenges and opportunities in the field of gut microbiome therapeutics.
A recent study shows that some bacterial strains are similar to the human host phylogeny, suggesting that they evolved alongside humans.
